{"bill": {"#text": "\n\t", "form": {"current-chamber": {"#tail": "\n\t\t", "#text": "IN THE SENATE OF THE UNITED STATES"}, "#text": "\n\t\t", "congress": {"#tail": "\n\t\t", "#text": "113th CONGRESS"}, "#tail": "\n\t", "legis-num": {"#tail": "\n\t\t", "#text": "S. 627"}, "official-title": {"#tail": "\n\t", "#text": "To provide incentives for investment in research and\n\t\t  development for new medicines, to enhance access to new medicines, and for\n\t\t  other purposes."}, "session": {"#tail": "\n\t\t", "#text": "1st Session"}, "distribution-code": {"#tail": "\n\t\t", "@display": "yes", "#text": "II"}, "action": {"action-date": {"#tail": "\n\t\t\t", "@date": "20130320", "#text": "March 20, 2013"}, "#tail": "\n\t\t", "action-desc": {"#tail": "\n\t\t", "#text": "\n        ", "sponsor": {"#tail": " introduced\n\t\t\t the following bill; which was read twice and referred to the\n\t\t\t ", "#text": "Mr. Sanders", "@name-id": "S313"}, "committee-name": {"#tail": "\n      ", "@committee-id": "SSHR00", "#text": "Committee on Health, Education, Labor,\n\t\t\t and Pensions"}}, "#text": "\n\t\t\t"}, "legis-type": {"#tail": "\n\t\t", "#text": "A BILL"}}, "@bill-stage": "Introduced-in-Senate", "@public-private": "public", "legis-body": {"#tail": "\n", "section": [{"@section-type": "section-one", "#tail": "\n    ", "text": {"#tail": "\n\t\t", "quote": {"short-title": {"#tail": "\n        ", "#text": "Medical Innovation Prize Fund\n\t\t\t Act"}, "#tail": ".", "#text": "\n          "}, "#text": "This Act may be cited as\n\t\t\t the ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "1."}, "header": {"#tail": "\n      ", "#text": "Short\n\t\t\t title"}, "#text": "\n      ", "@id": "S1"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " makes the following\n\t\t\t findings:", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}, "#text": "\n        ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "2."}, "header": {"#tail": "\n      ", "#text": "Findings"}, "paragraph": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "The development of new medicines and\n\t\t\t vaccines is necessary to improve health care outcomes.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(1)"}, "@id": "id9BE7E08F01604AC39FBBC141A225CA37", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "Market exclusivity for new products is an\n\t\t\t expensive, inefficient, and unfair mechanism to reward investments in new\n\t\t\t products.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(2)"}, "@id": "id714545F40B194831B081962E440FFF37", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "By de-linking research and development\n\t\t\t incentives from product prices, and by eliminating legal monopolies to sell\n\t\t\t products, it is possible to induce investments that are medically more\n\t\t\t important, procure products at low prices from competitive suppliers, radically\n\t\t\t lower pricing barriers for access to new medicines, reduce wasteful marketing\n\t\t\t and research and development activities, and dramatically lower the overall\n\t\t\t costs of acquiring innovation, while expanding access to that\n\t\t\t innovation.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(3)"}, "@id": "idBDE0F196AE1D4D32A097A3EBDF23BBC1", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "By funding innovation prizes at .55 percent\n\t\t\t of gross domestic product, the United States would provide more than\n\t\t\t $86,000,000,000 in rewards for successful innovation in 2012.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(4)"}, "@id": "id3ED537E6332D4D87A652912A5B2ED47C", "#text": "\n        "}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "#text": "The development of new medicines benefits\n\t\t\t from greater sharing of knowledge, data, materials, and technologies.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(5)"}, "@id": "id57CAB2EE841C41B597FFD8733B4D02F1", "#text": "\n        "}], "#text": "\n      ", "@id": "idB59CCA7C2E3C47B583F2BC606B6D449A"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t", "#text": "It is the purpose of this Act to provide\n\t\t\t incentives to encourage entities to invest in research and development of new\n\t\t\t medicines and to share knowledge, data, materials, and technology, through the\n\t\t\t establishment of a Medical Innovation Prize Fund, while enhancing access to\n\t\t\t such medicines by eliminating legal monopolies on the manufacture,\n\t\t\t distribution, and sale of such medicines.", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "3."}, "header": {"#tail": "\n      ", "#text": "Purpose"}, "#text": "\n      ", "@id": "id51F6A98546164472AB815AEE8C2BFFE8"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "#text": "In this Act:", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "4."}, "header": {"#tail": "\n      ", "#text": "Definitions"}, "paragraph": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "term": {"#tail": " has the meaning\n\t\t\t given such term in ", "#text": "biological product"}, "#text": "The term ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "section 351 of the Public Health Service Act", "@value": "Public Health Service Act/s:351"}, {"#tail": ")", "@entity-type": "uscode", "#text": "42 U.S.C.\n\t\t\t 262", "@value": "usc/42/262"}], "@entity-type": "law-citation", "#text": "\n            "}}, "enum": {"#tail": "\n        ", "#text": "(1)"}, "header": {"#tail": "\n        ", "#text": "Biological\n\t\t\t product"}, "#text": "\n        ", "@id": "id48F480C6D1CD4E6689EA11CA6CBDB331"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "quote": {"#tail": " means the ", "#text": "Board"}, "#text": "The\n\t\t\t term ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " established under ", "@entity-type": "federal-body", "#text": "Board of Trustees for the Fund for Medical\n\t\t\t Innovation Prizes", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, {"#tail": ".", "@entity-type": "act", "#text": "section 7", "@value": "Medical Innovation Prize Fund Act/s:7", "@proposed": "true"}]}, "enum": {"#tail": "\n        ", "#text": "(2)"}, "header": {"#tail": "\n        ", "#text": "Board"}, "#text": "\n        ", "@id": "IDa0e0bf5f444747d1a73a4a795375488b"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "term": {"#tail": " has the meaning given such term in ", "#text": "drug"}, "#text": "The\n\t\t\t term ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 201 of the\n\t\t\t Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:201"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "21 U.S.C. 321", "@value": "usc/21/321"}, "@parsable-cite": "usc/21/321", "#text": "\n              ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n        ", "#text": "(3)"}, "header": {"#tail": "\n        ", "#text": "Drug"}, "#text": "\n        ", "@id": "IDdf9e86b200ec451ba70dcc37aa4c0f34"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "section 6", "@value": "Medical Innovation Prize Fund Act/s:6", "@proposed": "true"}, "term": {"#tail": " means the Fund for Medical Innovation Prizes established\n\t\t\t under ", "#text": "Fund"}, "#text": "The\n\t\t\t term "}, "enum": {"#tail": "\n        ", "#text": "(4)"}, "header": {"#tail": "\n        ", "#text": "Fund"}, "#text": "\n        ", "@id": "ID0efc3a666a3449719e04b253a6dc2f5c"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "term": {"#tail": " means the\n\t\t\t approval of an application under ", "#text": "market clearance"}, "#text": "The term ", "{http://namespaces.cato.org/catoxml}entity": [{"#tail": " or the approval of a biologics license application\n\t\t\t under ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 505 of the Federal Food, Drug, and\n\t\t\t Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "21 U.S.C. 355", "@value": "usc/21/355"}, "@parsable-cite": "usc/21/355", "#text": "\n              ", "@legal-doc": "usc"}}, {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "subsection (a) of section 351 of the Public Health Service Act", "@value": "Public Health Service Act/s:351/ss:a"}, {"#tail": ")", "@entity-type": "uscode", "#text": "42 U.S.C.\n\t\t\t 262", "@value": "usc/42/262"}], "@entity-type": "law-citation", "#text": "\n            "}]}, "enum": {"#tail": "\n        ", "#text": "(5)"}, "header": {"#tail": "\n        ", "#text": "Market\n\t\t\t clearance"}, "#text": "\n        ", "@id": "ID588e3245aacb43f080ff70fee5e99d3c"}], "#text": "\n      ", "@id": "idAC4F063505AE4B419A14FA0D78F68459"}, {"#tail": "\n    ", "enum": {"#tail": "\n      ", "#text": "5."}, "header": {"#tail": "\n\t\t\t", "#text": "Elimination of\n\t\t\t exclusive rights to market drugs and biological products"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", relevant\n\t\t\t provisions of the ", "@entity-type": "uscode", "#text": "title 35, United States Code", "@value": "usc/35"}, "#text": "Notwithstanding ", "{http://namespaces.cato.org/catoxml}entity": [{"#tail": "\n\t\t\t (including amendments made by the ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act"}, {"#tail": ")", "@entity-type": "uscode", "#text": "\n              ", "external-xref": {"#tail": "\n            ", "@parsable-cite": "usc/21/301", "#text": "21 U.S.C. 301 et seq.", "@legal-doc": "usc"}, "@value": "usc/21/301/etseq"}], "@entity-type": "law-citation", "#text": "\n            "}, {"#tail": ", the ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "Drug Price Competition and Patent Term\n\t\t\t Restoration Act of 1984", "@value": "Drug Price Competition and Patent Term Restoration Act of 1984"}, {"#tail": "))", "@entity-type": "act", "#text": "\n              ", "term": {"#tail": "\n            ", "#text": "Hatch-Waxman Act"}, "@value": "Hatch-Waxman Act"}], "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": "; commonly referred to as the\n\t\t\t ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "public-law", "#text": "Public Law 98\u2013417", "@value": "public-law/98/417"}, "@parsable-cite": "pl/98/417", "#text": "\n              ", "@legal-doc": "public-law"}}, {"#tail": ", and any other provision of\n\t\t\t law providing any patent right or exclusive marketing period for any drug,\n\t\t\t biological product, or manufacturing process for a drug or biological product\n\t\t\t (such as pediatric extensions under ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Medicare Prescription Drug, Improvement,\n\t\t\t and Modernization Act of 2003", "@value": "Medicare Prescription Drug, Improvement, and Modernization Act of 2003"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "public-law", "#text": "Public Law 108\u2013173", "@value": "public-law/108/173"}, "@parsable-cite": "pl/108/173", "#text": "\n              ", "@legal-doc": "public-law"}}, {"#tail": " or orphan drug marketing exclusivity under\n\t\t\t ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "section 505A of the Federal Food, Drug, and\n\t\t\t Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505A"}, {"#tail": ")", "@entity-type": "uscode", "#text": "\n              ", "external-xref": {"#tail": "\n            ", "@parsable-cite": "usc/21/355a", "#text": "21 U.S.C. 355a", "@legal-doc": "usc"}, "@value": "usc/21/355a"}], "@entity-type": "law-citation", "#text": "\n            "}, {"#tail": "), no person\n\t\t\t shall have the right to exclusively manufacture, distribute, sell, or use a\n\t\t\t drug, a biological product, or a manufacturing process for a drug or biological\n\t\t\t product in interstate commerce, including the exclusive right to rely on health\n\t\t\t registration data or the 30-month stay-of-effectiveness period for Orange Book\n\t\t\t patents under ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "subchapter B of chapter V of such Act", "@value": "Federal Food, Drug, and Cosmetic Act/ch:V/sch:B"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "21 U.S.C. 360aa et seq.", "@value": "usc/21/360aa/etseq"}, "@parsable-cite": "usc/21/360aa", "#text": "\n              ", "@legal-doc": "usc"}}, {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 505(j) of such Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "21 U.S.C. 355(j)", "@value": "usc/21/355/j"}, "@parsable-cite": "usc/21/355", "#text": "\n              ", "@legal-doc": "usc"}}]}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "In\n\t\t\t general"}, "#text": "\n        ", "@id": "id4542086738434762813C97763BCB0F47"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", ", "@entity-type": "act", "#text": "sections 9", "@value": "Medical Innovation Prize Fund Act/s:9", "@proposed": "true"}, {"#tail": ", or ", "@entity-type": "act", "#text": "10", "@value": "Medical Innovation Prize Fund Act/s:10", "@proposed": "true"}, {"#tail": " shall receive such payments\u2014", "@entity-type": "act", "#text": "11", "@value": "Medical Innovation Prize Fund Act/s:11", "@proposed": "true"}], "#text": "A\n\t\t\t person that is eligible for prize payments from the Fund as provided for in\n\t\t\t "}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Remuneration"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "; and", "@entity-type": "act", "#text": "subsection (a)", "@value": "Medical Innovation Prize Fund Act/s:5/ss:a", "@proposed": "true"}, "#text": "in lieu of any\n\t\t\t remuneration the person would have otherwise received for the exclusive\n\t\t\t marketing, distribution, sale, or use of a drug, biological product, or\n\t\t\t manufacturing process for a drug or biological product but for the application\n\t\t\t of "}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "ID5c47bc49188e48e6aa134ffdd4724958", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "in addition to\n\t\t\t any other remuneration that such person receives by reason of the nonexclusive\n\t\t\t marketing, distribution, sale, or use of the drug, biological product, or\n\t\t\t manufacturing process for a drug or biological product."}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "ID3f38317d248a46fb86cfc32eef4fb6d1", "#text": "\n          "}], "#text": "\n        ", "@id": "id26FCFC726739485BB4BCC9433FF15889"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "#text": "This\n\t\t\t section shall apply only with respect to the marketing, distribution, sale, or\n\t\t\t use of a drug, a biological product, or a manufacturing process for a drug or\n\t\t\t biological product that occurs on or after October 1, 2014."}, "enum": {"#tail": "\n        ", "#text": "(c)"}, "header": {"#tail": "\n        ", "#text": "Application"}, "#text": "\n        ", "@id": "id1EEAA35776814DFE84D5F91E5B945091"}], "#text": "\n      ", "@id": "idA2691CB212AF4F31A674B8232411DF32"}, {"#tail": "\n    ", "enum": {"#tail": "\n      ", "#text": "6."}, "header": {"#tail": "\n\t\t\t", "#text": "Fund for medical\n\t\t\t innovation prizes"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "subsection (c)", "@value": "Medical Innovation Prize Fund Act/s:6/ss:c", "@proposed": "true"}, "term": {"#tail": ", which shall\n\t\t\t consist of amounts appropriated to the Fund and amounts credited to the Fund\n\t\t\t under ", "#text": "Fund for Medical Innovation Prizes"}, "#text": "There\n\t\t\t is hereby established in the Treasury of the United States a revolving fund to\n\t\t\t be known as the "}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "Establishment"}, "#text": "\n        ", "@id": "id6CAB3071EDA742E29A74FAB381A95B11"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ",\n\t\t\t subject to ", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, {"#tail": ", for the purpose of carrying out this Act.", "@entity-type": "act", "#text": "section 17(c)", "@value": "Medical Innovation Prize Fund Act/s:17/ss:c", "@proposed": "true"}], "#text": "Amounts in the Fund shall be available to the "}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Availability of\n\t\t\t funds"}, "#text": "\n        ", "@id": "id2EE2CDC3798D47C7AC53E740E10B975E"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall credit\n\t\t\t to the Fund the interest on, and the proceeds from sale or redemption of,\n\t\t\t obligations held in the Fund.", "@entity-type": "federal-body", "#text": "Secretary of the Treasury", "@entity-id": "2000"}, "#text": "The "}, "enum": {"#tail": "\n        ", "#text": "(c)"}, "header": {"#tail": "\n        ", "#text": "Amounts\n\t\t\t credited to the Fund"}, "#text": "\n        ", "@id": "idE936F2E332E8424B83C792679D151276"}], "#text": "\n      ", "@id": "id2F930875A2E149278138150494AC13A5"}, {"#tail": "\n    ", "enum": {"#tail": "\n      ", "#text": "7."}, "header": {"#tail": "\n\t\t\t", "#text": "Board of\n\t\t\t trustees for the Fund"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "federal-body", "#text": "Board of Trustees for the Fund for Medical Innovation\n\t\t\t Prizes", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, "#text": "There\n\t\t\t is hereby established (as a permanent, independent establishment in the\n\t\t\t executive branch) a "}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "Establishment"}, "#text": "\n        ", "@id": "idE9C7FB0536A14498B1556800B9DF9C46"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall be composed of 13 members, including\u2014", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, "#text": "The\n\t\t\t "}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Membership"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ";", "@entity-type": "federal-body", "#text": "Administrator\n\t\t\t of the Centers for Medicare & Medicaid Services", "@entity-id": "7530"}, "#text": "the "}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "ID0541197ae0b3421282cf60fa917903cf", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ";", "@entity-type": "federal-body", "#text": "Commissioner of Food and Drugs", "@entity-id": "7524"}, "#text": "the "}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "IDc6745e95cc544804ac1206e2683776ec", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ";", "@entity-type": "federal-body", "#text": "Director of the National Institutes of\n\t\t\t\tHealth", "@entity-id": "7529"}, "#text": "the "}, "enum": {"#tail": "\n          ", "#text": "(3)"}, "@id": "ID637dbb695fa74920b1383302c4dd7e6e", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "; and", "@entity-type": "federal-body", "#text": "Director of\n\t\t\t the Centers for Disease Control and Prevention", "@entity-id": "7523"}, "#text": "the "}, "enum": {"#tail": "\n          ", "#text": "(4)"}, "@id": "IDab911002e137473294ac0a165587e4e8", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", with the advice and consent of the ", "@entity-type": "federal-body", "#text": "President", "@entity-id": "1100"}, {"#tail": ", of\n\t\t\t which\u2014", "@entity-type": "federal-body", "#text": "Senate", "@entity-id": "0010"}], "#text": "9 individuals to\n\t\t\t be appointed by the "}, "enum": {"#tail": "\n          ", "#text": "(5)"}, "#text": "\n          ", "@id": "IDb6556662d2de4cf9ae20efed45103cb5", "subparagraph": [{"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "2 shall be\n\t\t\t representatives of businesses that provide health insurance to\n\t\t\t employees;"}, "enum": {"#tail": "\n            ", "#text": "(A)"}, "@id": "ID60a8379b41a14560897cebab4a902f30", "#text": "\n            "}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ";", "@entity-type": "act", "#text": "section 17", "@value": "Medical Innovation Prize Fund Act/s:17", "@proposed": "true"}, "#text": "2 shall be\n\t\t\t representatives of entities that provide health insurance and contribute to the\n\t\t\t co-funding of the Fund for Medical Innovation Prizes under "}, "enum": {"#tail": "\n            ", "#text": "(B)"}, "@id": "ID8c53b145a62b424f8c22f9bdea2b64e5", "#text": "\n            "}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "2 shall be\n\t\t\t representatives of the medical research and development sector, including at\n\t\t\t least 1 representative of the nonprofit private medical research and\n\t\t\t development sector; and"}, "enum": {"#tail": "\n            ", "#text": "(C)"}, "@id": "ID15ee23a6fa784e64bfe65e45defb8ae9", "#text": "\n            "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "3 shall be\n\t\t\t representatives of consumer and patient interests, including at least one\n\t\t\t representative of patients suffering from orphan diseases."}, "enum": {"#tail": "\n            ", "#text": "(D)"}, "@id": "ID5ce02b7554684247a64cbe42ee559511", "#text": "\n            "}]}], "#text": "\n        ", "@id": "idDC0D1D20FF93491AB3A99F9F876DAB3F"}, {"#tail": "\n      ", "enum": {"#tail": "\n        ", "#text": "(c)"}, "header": {"#tail": "\n\t\t\t\t", "#text": "Terms"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", each member\n\t\t\t appointed to the ", "@entity-type": "act", "#text": "paragraph (2)", "@value": "Medical Innovation Prize Fund Act/s:7/ss:c/p:2", "@proposed": "true"}, {"#tail": " under ", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, {"#tail": " shall be appointed for a term of\n\t\t\t 4 years.", "@entity-type": "act", "#text": "subsection (b)(5)", "@value": "Medical Innovation Prize Fund Act/s:7/ss:b/p:5", "@proposed": "true"}], "#text": "Except as provided in "}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "header": {"#tail": "\n          ", "#text": "In\n\t\t\t general"}, "#text": "\n          ", "@id": "id89F0057B753D48D493FAE108442F66DB"}, {"#tail": "\n      ", "@id": "IDf5e6c17ce4af4d0ebf73137911b9e8b6", "enum": {"#tail": "\n          ", "#text": "(2)"}, "header": {"#tail": "\n          ", "#text": "Terms of\n\t\t\t initial appointees"}, "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " at the time of\n\t\t\t appointment, of the members first appointed to the ", "@entity-type": "federal-body", "#text": "President", "@entity-id": "1100"}, {"#tail": " under ", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, {"#tail": "\u2014", "@entity-type": "act", "#text": "subsection\n\t\t\t (b)(5)", "@value": "Medical Innovation Prize Fund Act/s:7/ss:b/p:5", "@proposed": "true"}], "#text": "As designated by the "}, "#text": "\n          ", "subparagraph": [{"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "5 members shall\n\t\t\t be appointed for a term of 4 years; and"}, "enum": {"#tail": "\n            ", "#text": "(A)"}, "@id": "IDaf7f98d767524ead9103940cfc4f0ede", "#text": "\n            "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "4 members shall\n\t\t\t be appointed for a term of 2 years."}, "enum": {"#tail": "\n            ", "#text": "(B)"}, "@id": "IDc759e6f24bb44f8a864383a12563ae5e", "#text": "\n            "}]}], "#text": "\n        ", "@id": "id322A2924BF6F4F539D139319331788BA"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " appointed to fill a vacancy occurring before the expiration\n\t\t\t of the term for which the member's predecessor was appointed shall be appointed\n\t\t\t only for the remainder of that term. A member of the ", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, {"#tail": " may serve after the\n\t\t\t expiration of that member's term until a successor has taken office.", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}], "#text": "Any\n\t\t\t member of the "}, "enum": {"#tail": "\n        ", "#text": "(d)"}, "header": {"#tail": "\n        ", "#text": "Vacancies"}, "#text": "\n        ", "@id": "idE29A461E4D814B7FBC22D28655FDCFAD"}, {"#tail": "\n      ", "enum": {"#tail": "\n        ", "#text": "(e)"}, "header": {"#tail": "\n\t\t\t\t", "#text": "Compensation\n\t\t\t and travel expenses"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, "#text": "Members\n\t\t\t of the Board shall each be paid not less than the daily equivalent of level IV\n\t\t\t of the Executive Schedule for each day (including travel time) during which\n\t\t\t they are engaged in the actual performance of the duties of the "}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "header": {"#tail": "\n          ", "#text": "Compensation"}, "#text": "\n          ", "@id": "ID703675768ab14635a00560b8fd292aee"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "uscode", "#text": "subchapter I of ", "external-xref": {"#tail": " of title 5, United States\n\t\t\t Code", "@parsable-cite": "usc-chapter/5/57", "#text": "chapter 57", "@legal-doc": "usc-chapter"}, "@value": "usc-chapter/5/57/I"}, "#text": "Each member of the Board shall receive travel expenses,\n\t\t\t including per diem in lieu of subsistence, in accordance with applicable\n\t\t\t provisions under "}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "header": {"#tail": "\n          ", "#text": "Travel\n\t\t\t expenses"}, "#text": "\n          ", "@id": "IDcad78108544a4c62abc2f2ff4b1bff53"}], "#text": "\n        ", "@id": "ID4e46761daf41482fae8d78780590396e"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " and\n\t\t\t any other officers of the ", "@entity-type": "federal-body", "#text": "Chairperson", "@value": "Chairperson of the Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, {"#tail": ". The ", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, {"#tail": " and any such officers shall be\n\t\t\t elected for a term of 2 years.", "@entity-type": "federal-body", "#text": "Chairperson", "@value": "Chairperson of the Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}], "#text": "The members of the Board shall elect a "}, "enum": {"#tail": "\n        ", "#text": "(f)"}, "header": {"#tail": "\n        ", "#text": "Chairperson;\n\t\t\t Officers"}, "#text": "\n        ", "@id": "IDcf37164d52f043e1bece9895f830e685"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " may appoint and fix the pay of such additional personnel as the ", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, {"#tail": "\n\t\t\t considers appropriate. The staff of the ", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, {"#tail": " shall be appointed subject to the\n\t\t\t provisions of ", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, {"#tail": ", governing appointments in the\n\t\t\t competitive service, and shall be paid in accordance with the provisions of\n\t\t\t ", "@entity-type": "uscode", "#text": "title 5, United States Code", "@value": "usc/5"}, {"#tail": " and ", "@entity-type": "uscode", "#text": "chapter 51", "@value": "usc-chapter/5/51"}, {"#tail": " relating to\n\t\t\t classification and General Schedule pay rates.", "@entity-type": "uscode", "#text": "subchapter III of chapter 53 of such title", "@value": "usc-chapter/5/53/III"}], "#text": "The\n\t\t\t "}, "enum": {"#tail": "\n        ", "#text": "(g)"}, "header": {"#tail": "\n        ", "#text": "Staff"}, "#text": "\n        ", "@id": "IDbcc4fb53f1064d5ba81def7fc6de1d6d"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " may procure temporary and intermittent\n\t\t\t services under ", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, {"#tail": ".", "@entity-type": "uscode", "#text": "\n            ", "external-xref": {"#tail": " of title 5, United States Code", "@parsable-cite": "usc/5/3109", "#text": "section 3109(b)", "@legal-doc": "usc"}, "@value": "usc/5/3109/b"}], "#text": "The "}, "enum": {"#tail": "\n        ", "#text": "(h)"}, "header": {"#tail": "\n        ", "#text": "Experts and\n\t\t\t consultants"}, "#text": "\n        ", "@id": "ID690c9454b38f42f0b81e2176c6822c61"}], "#text": "\n      ", "@id": "id697AB1A112C242E7B8B346E3E342DB15"}, {"#tail": "\n    ", "enum": {"#tail": "\n      ", "#text": "8."}, "header": {"#tail": "\n\t\t\t", "#text": "Powers and\n\t\t\t duties of the Board"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall\u2014", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, "#text": "The\n\t\t\t "}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "Duties"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "award prize\n\t\t\t payments for medical innovation in accordance with this Act; and"}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "ID177301bd39c6439287496f714810419a", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " under ", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}, {"#tail": ".", "@entity-type": "act", "#text": "section 16", "@value": "Medical Innovation Prize Fund Act/s:16", "@proposed": "true"}], "#text": "submit a report\n\t\t\t to the "}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "ID1cc2d046b7124196b9f125ae36a638e8", "#text": "\n          "}], "#text": "\n        ", "@id": "id7106D158CC534660922EC29A24A8DCDA"}, {"#tail": "\n    ", "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n\t\t\t\t", "#text": "Powers of\n\t\t\t Board"}, "paragraph": [{"#tail": "\n        ", "subparagraph": [{"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " may, for the purpose of carrying out this Act,\n\t\t\t hold hearings, sit and act at times and places, take testimony, and receive\n\t\t\t evidence as the ", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, {"#tail": " considers appropriate.", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}], "#text": "The "}, "enum": {"#tail": "\n            ", "#text": "(A)"}, "header": {"#tail": "\n            ", "#text": "In\n\t\t\t general"}, "#text": "\n            ", "@id": "id1DC38CC86F8E40FF82ED5AC5D49622E7"}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " are appointed under ", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, {"#tail": " and confirmed, the ", "@entity-type": "act", "#text": "section 7(b)(5)", "@value": "Medical Innovation Prize Fund Act/s:7/ss:b/p:5", "@proposed": "true"}, {"#tail": " shall\n\t\t\t conduct its first meeting.", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}], "#text": "Not later than 30 days after the initial members of the\n\t\t\t "}, "enum": {"#tail": "\n            ", "#text": "(B)"}, "header": {"#tail": "\n            ", "#text": "First\n\t\t\t meeting"}, "#text": "\n            ", "@id": "ID27c72a1317f848bf91999ca1ae8e35c8"}], "enum": {"#tail": "\n          ", "#text": "(1)"}, "header": {"#tail": "\n\t\t\t\t\t", "#text": "Hearings and\n\t\t\t sessions"}, "#text": "\n          ", "@id": "idDBAC24FAE7284F95AD44382EBBE28DFE"}, {"#tail": "\n        ", "subparagraph": [{"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " are appointed under ", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, {"#tail": " and confirmed, the ", "@entity-type": "act", "#text": "section 7(b)(5)", "@value": "Medical Innovation Prize Fund Act/s:7/ss:b/p:5", "@proposed": "true"}, {"#tail": " shall\n\t\t\t establish such policies and procedures as may be appropriate to carry out this\n\t\t\t Act.", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}], "#text": "Not later than 1 year after the initial members of the\n\t\t\t "}, "enum": {"#tail": "\n            ", "#text": "(A)"}, "header": {"#tail": "\n            ", "#text": "In\n\t\t\t general"}, "#text": "\n            ", "@id": "id055DAB0F697C4AF1B0BECC3F38A54943"}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall require that\n\t\t\t any determination of the ", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, {"#tail": " be made by not less than a majority vote of the\n\t\t\t members of the Board.", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}], "#text": "The policies and procedures of the "}, "enum": {"#tail": "\n            ", "#text": "(B)"}, "header": {"#tail": "\n            ", "#text": "Majority\n\t\t\t vote"}, "#text": "\n            ", "@id": "id94D3F7387BC14E12845B3E6C1A910542"}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall comply\n\t\t\t with ", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, {"#tail": ".", "@entity-type": "uscode", "#text": "subchapter II of ", "external-xref": {"#tail": " of title 5, United States Code", "@parsable-cite": "usc-chapter/5/5", "#text": "chapter 5", "@legal-doc": "usc-chapter"}, "@value": "usc-chapter/5/5/II"}], "#text": "The policies and procedures of the "}, "enum": {"#tail": "\n            ", "#text": "(C)"}, "header": {"#tail": "\n            ", "#text": "Administrative\n\t\t\t procedures"}, "#text": "\n            ", "@id": "IDf1d1d34bcd594082831dd67c69108755"}, {"#tail": "\n        ", "clause": [{"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " and ", "@entity-type": "uscode", "#text": "sections ", "external-xref": {"#tail": "\n                  ", "@parsable-cite": "usc/5/552", "#text": "552", "@legal-doc": "usc"}, "@value": "usc/5/552"}, {"#tail": " (commonly referred to as\n\t\t\t the ", "@entity-type": "uscode", "#text": "\n                    ", "external-xref": {"#tail": " of title 5, United States Code", "@parsable-cite": "usc/5/552b", "#text": "552b", "@legal-doc": "usc"}, "@value": "usc/5/552a"}], "term": [{"#tail": " and the ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                  ", "@entity-type": "act", "#text": "Freedom of Information Act", "@value": "Freedom of Information Act"}, "#text": "\n                    "}, {"#tail": ", respectively); and", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                  ", "@entity-type": "act", "#text": "Government in the\n\t\t\t Sunshine Act", "@value": "Government in the Sunshine Act"}, "#text": "\n                    "}], "#text": "comply with\n\t\t\t \n                  "}, "enum": {"#tail": "\n              ", "#text": "(i)"}, "@id": "ID3c8b9a06923b4f409fca221307104dfd", "#text": "\n              "}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " are transparent and are supported by\n\t\t\t a description of the methods, data sources, assumptions, outcomes, and related\n\t\t\t information that will allow the public to understand how the ", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, {"#tail": " reaches its\n\t\t\t criteria-setting and award decisions.", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}], "#text": "ensure that the\n\t\t\t proceedings and deliberations of the "}, "enum": {"#tail": "\n              ", "#text": "(ii)"}, "@id": "ID92e107e8f0da439e93a501f486bf803a", "#text": "\n              "}], "enum": {"#tail": "\n            ", "#text": "(D)"}, "header": {"#tail": "\n            ", "#text": "Transparency"}, "text": {"#tail": "\n\t\t\t\t\t\t", "#text": "The\n\t\t\t policies and procedures of the Board shall\u2014"}, "#text": "\n            ", "@id": "ID9c1e9b720295479eb387218d65a46555"}], "enum": {"#tail": "\n          ", "#text": "(2)"}, "header": {"#tail": "\n\t\t\t\t\t", "#text": "Policies and\n\t\t\t procedures"}, "#text": "\n          ", "@id": "id5BE9B8C680C14335BF33C5F1A8C6D860"}, {"#tail": "\n        ", "@id": "id403A03CF7F9046A1879C9F2CD0D7FA5B", "enum": {"#tail": "\n          ", "#text": "(3)"}, "header": {"#tail": "\n          ", "#text": "Expert advisory\n\t\t\t committees"}, "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " in carrying out this Act, the\n\t\t\t ", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, {"#tail": " shall establish independent expert advisory committees, including\n\t\t\t committees on the following:", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}], "#text": "To assist the "}, "#text": "\n          ", "subparagraph": [{"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "Economic\n\t\t\t evaluation of therapeutic benefits."}, "enum": {"#tail": "\n            ", "#text": "(A)"}, "@id": "ID81180be7472447ca848bd8b792bd65b6", "#text": "\n            "}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "Business models\n\t\t\t and incentive structures for innovation."}, "enum": {"#tail": "\n            ", "#text": "(B)"}, "@id": "IDeec6a5a7333e4f1b96578c4849c7afe1", "#text": "\n            "}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "Research and\n\t\t\t development priorities."}, "enum": {"#tail": "\n            ", "#text": "(C)"}, "@id": "ID89c3af45b73149b583940abd0e431325", "#text": "\n            "}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "Orphan\n\t\t\t diseases."}, "enum": {"#tail": "\n            ", "#text": "(D)"}, "@id": "IDca12ea2f676d438fabd3f322335f2ce4", "#text": "\n            "}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "Financial control\n\t\t\t and auditing."}, "enum": {"#tail": "\n            ", "#text": "(E)"}, "@id": "ID6c1a5e8ffbf944b4baf7dac451bad08d", "#text": "\n            "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "Open source\n\t\t\t biomedical science."}, "enum": {"#tail": "\n            ", "#text": "(F)"}, "@id": "IDfc313de07dd94f01a54f2d972a04ba66", "#text": "\n            "}]}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " may, if\n\t\t\t authorized by the ", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, {"#tail": ", take any action which the ", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, {"#tail": " is authorized to take\n\t\t\t under this Act.", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}], "#text": "Any member or agent of the "}, "enum": {"#tail": "\n          ", "#text": "(4)"}, "header": {"#tail": "\n          ", "#text": "Powers of\n\t\t\t members and agents"}, "#text": "\n          ", "@id": "IDe225064b5d4d43ad844c5bd3828cbefa"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " may use the United States mails in the same manner and under the same\n\t\t\t conditions as other departments and agencies of the United States.", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, "#text": "The\n\t\t\t "}, "enum": {"#tail": "\n          ", "#text": "(5)"}, "header": {"#tail": "\n          ", "#text": "Mails"}, "#text": "\n          ", "@id": "ID6e5eddbb200b4e6d92a8bcb01ffd62eb"}], "#text": "\n        ", "@id": "idA37710A2C8BA4BA5A44A559452C387AD"}], "#text": "\n      ", "@id": "id185970A0A0164CB089AF828E0351B508"}, {"#tail": "\n    ", "enum": {"#tail": "\n      ", "#text": "9."}, "header": {"#tail": "\n\t\t\t", "#text": "Prize payments\n\t\t\t for medical innovation"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall award to\n\t\t\t persons described in ", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, {"#tail": " prize payments for medical innovation\n\t\t\t relating to a drug, a biological product, or a new manufacturing process for a\n\t\t\t drug or biological product.", "@entity-type": "act", "#text": "subsection (b)", "@value": "Medical Innovation Prize Fund Act/s:9/ss:b", "@proposed": "true"}], "#text": "For\n\t\t\t fiscal year 2015, and each subsequent fiscal year, the "}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "Award"}, "#text": "\n        ", "@id": "id9D2AE6D3FF96404A80D1A36C391DD05F"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " for medical\n\t\t\t innovation relating to a drug, a biological product, or a manufacturing\n\t\t\t process, a person shall be\u2014", "@entity-type": "act", "#text": "subsection (a)", "@value": "Medical Innovation Prize Fund Act/s:9/ss:a", "@proposed": "true"}, "#text": "To\n\t\t\t be eligible to receive a prize payment under "}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Eligibility"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "in the case of a\n\t\t\t drug or biological product, the first person to receive market clearance with\n\t\t\t respect to the drug or biological product;"}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "IDeffb8e30127849989c6a0532be3a5d50", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "in the case of a\n\t\t\t manufacturing process, the holder of the patent with respect to such process;\n\t\t\t or"}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "ID3b81b6e86b204f70b51ea26d9a555079", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "in the case of\n\t\t\t open source contributions, the persons or communities that openly shared\n\t\t\t knowledge, data, materials, and technology on a royalty-free and\n\t\t\t nondiscriminatory basis."}, "enum": {"#tail": "\n          ", "#text": "(3)"}, "@id": "ID25ab9f320b73417b8e933d274aca74b2", "#text": "\n          "}], "#text": "\n        ", "@id": "id843C2BC1E4114596A3C1E36255503CFD"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall, by regulation, establish criteria for the selection of recipients,\n\t\t\t and for determining the amount, of prize payments under this section. Such\n\t\t\t criteria shall include consideration of the following:", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, "#text": "The\n\t\t\t "}, "enum": {"#tail": "\n        ", "#text": "(c)"}, "header": {"#tail": "\n        ", "#text": "Criteria"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "The number of\n\t\t\t patients who would benefit from the drug, biological product, or manufacturing\n\t\t\t process involved, including (in cases of global neglected diseases, global\n\t\t\t infectious diseases, and other global public health priorities) the number of\n\t\t\t non-United States patients."}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "ID529a730c4a774da9b1e56e33adc3a729", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall provide for cases where drugs, biological products, or\n\t\t\t manufacturing processes are developed at roughly the same time, so that the\n\t\t\t comparison is to products that were not recently developed.", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, "#text": "The incremental\n\t\t\t therapeutic benefit of the drug, biological product, or manufacturing process\n\t\t\t involved as compared to existing drugs, biological products, and manufacturing\n\t\t\t processes available to treat the same disease or condition, except that the\n\t\t\t "}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "IDf3eb247158e64fccb2e051e3c7506417", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "The degree to\n\t\t\t which the drug, biological product, or manufacturing process involved addresses\n\t\t\t priority health care needs, including\u2014"}, "enum": {"#tail": "\n          ", "#text": "(3)"}, "#text": "\n          ", "@id": "ID3ecf87a2d07b491dac78fe30463c9ee0", "subparagraph": [{"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "current and\n\t\t\t emerging global infectious diseases;"}, "enum": {"#tail": "\n            ", "#text": "(A)"}, "@id": "ID2258044225d14e3381a48b148e1849e9", "#text": "\n            "}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "severe illnesses\n\t\t\t with small client populations (such as indications for which orphan designation\n\t\t\t has been granted under ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": "); and", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n\t\t\t (", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                ", "@entity-type": "act", "#text": "section 526 of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:526"}, "@entity-type": "act", "#text": "\n                  ", "@value": "Federal Food, Drug, and Cosmetic Act/s:526"}, "@entity-type": "law-citation", "#text": "\n                ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                ", "@entity-type": "uscode", "#text": "21 U.S.C. 360bb", "@value": "usc/21/360bb"}, "@parsable-cite": "usc/21/360bb", "#text": "\n                  ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n            ", "#text": "(B)"}, "@id": "ID65762bbb46ec45208cfa22c6d3243ad3", "#text": "\n            "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "neglected\n\t\t\t diseases that primarily afflict the poor in developing countries."}, "enum": {"#tail": "\n            ", "#text": "(C)"}, "@id": "IDb1f36a8e5aef48059f13b3b8a228a51d", "#text": "\n            "}]}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "Improved\n\t\t\t efficiency of manufacturing processes for drugs or biological processes."}, "enum": {"#tail": "\n          ", "#text": "(4)"}, "@id": "id9DD863E8B34748AEA8C0CD07A302E127", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "The extent to\n\t\t\t which knowledge, data, materials and technology that are openly shared have\n\t\t\t contributed to the successful development of new products or improved processes\n\t\t\t for manufacturing products."}, "enum": {"#tail": "\n          ", "#text": "(5)"}, "@id": "ID1456ba951b644fcba35c62f6c21bbd55", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "In the case of\n\t\t\t antibiotics or other products for which drug resistance is a significant public\n\t\t\t health problem, the expected life cycle benefits of the antibiotic or other\n\t\t\t product, with appropriate adjustments that reward the conservation of the\n\t\t\t resources, taking into account drug resistance that is related to use of the\n\t\t\t product."}, "enum": {"#tail": "\n          ", "#text": "(6)"}, "@id": "idB74B111DCAA747B1B9BDA77574C9BFD4", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "In the case of\n\t\t\t products used in stockpiles for potential threats to the public health, the\n\t\t\t risk adjusted benefits of stockpiling the products."}, "enum": {"#tail": "\n          ", "#text": "(7)"}, "@id": "id9D6BC6EF17CB4768B7312146F222829E", "#text": "\n          "}], "#text": "\n        ", "@id": "idAEAAB930D4C2422F9DF686408555F01D"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall comply with the\n\t\t\t following:", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, "#text": "In\n\t\t\t awarding prize payments under this section, the "}, "enum": {"#tail": "\n        ", "#text": "(d)"}, "header": {"#tail": "\n        ", "#text": "Requirements"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n\t\t\t shall continue to make prize payments for the existing drug, biological\n\t\t\t product, or manufacturing process to the degree that the new drug, biological\n\t\t\t product, or manufacturing process was based on or benefitted from the\n\t\t\t development of the existing drug, biological product, or manufacturing\n\t\t\t process.", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, "#text": "In cases where a\n\t\t\t new drug, biological product, or manufacturing process offers an improvement\n\t\t\t over an existing drug, biological product, or manufacturing process and the new\n\t\t\t drug, biological product, or manufacturing process competes with or replaces\n\t\t\t the existing drug, biological product, or manufacturing process, the "}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "ID8c6f662098464caaa2c1eb2dae80b777", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " may not\n\t\t\t make prize payments based on the identity of the person who manufactures,\n\t\t\t distributes, sells, or uses the drug, biological product, or manufacturing\n\t\t\t process involved.", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, "#text": "The "}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "IDa2236e0f31ad468bbada3fe077b142fc", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " may\n\t\t\t award prize payments for a drug, a biological product, or a manufacturing\n\t\t\t process for not more than 10 fiscal years, regardless of the term of any\n\t\t\t related patents.", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, "#text": "The "}, "enum": {"#tail": "\n          ", "#text": "(3)"}, "@id": "IDb1fa95ce80a640678e10f04e4e0c6e1f", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " may not award a prize payment for any single drug, biological\n\t\t\t product, or manufacturing process in an amount that exceeds 5 percent of the\n\t\t\t total amount appropriated to the Fund for that year.", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, "#text": "For any fiscal\n\t\t\t year, the "}, "enum": {"#tail": "\n          ", "#text": "(4)"}, "@id": "IDff8fa208c1334ec887931abe5c2a2822", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall determine\n\t\t\t whether and in what amount to award a prize payment for the drug or biological\n\t\t\t product not later than the end of the fourth full calendar-year quarter\n\t\t\t following the calendar-year quarter in which the drug or biological product\n\t\t\t receives market clearance.", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, "#text": "For every drug or\n\t\t\t biological product that receives market clearance, the "}, "enum": {"#tail": "\n          ", "#text": "(5)"}, "@id": "ID8a5aac503fef4558acc4ecaa690675a6", "#text": "\n          "}], "#text": "\n        ", "@id": "id20131C784F8F4D46B0476C9E30B3F6FD"}], "#text": "\n      ", "@id": "id5BBFFA2944B34E19BD46B8142A04FA3F"}, {"#tail": "\n    ", "enum": {"#tail": "\n      ", "#text": "10."}, "header": {"#tail": "\n\t\t\t", "#text": "Prizes for\n\t\t\t priority research and development"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall establish and may periodically modify minimum levels of funding\n\t\t\t under ", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, {"#tail": " for priority research and development.", "@entity-type": "act", "#text": "section 9", "@value": "Medical Innovation Prize Fund Act/s:9", "@proposed": "true"}], "#text": "For fiscal year 2015, and each subsequent fiscal year,\n\t\t\t the "}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "Minimum levels\n\t\t\t of funding"}, "#text": "\n        ", "@id": "id850C57440E504AFF96F4238F642F331C"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall use (subject to the establishment or modification of an\n\t\t\t applicable minimum level of funding under ", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, {"#tail": ") not less than\u2014", "@entity-type": "act", "#text": "subsection (a)", "@value": "Medical Innovation Prize Fund Act/s:10/ss:a", "@proposed": "true"}], "#text": "Of the amount appropriated to the Fund for a fiscal year,\n\t\t\t the "}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Initial minimum\n\t\t\t levels"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "4 percent of such\n\t\t\t amount for global neglected diseases;"}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "ID070d58dd7ad34161a84f9176da4a41d3", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "10 percent of\n\t\t\t such amount for orphan diseases; and"}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "ID216cab91f7234e6b90b64fe87b7e2a1d", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "4 percent of such\n\t\t\t amount for global infectious diseases and other global public health\n\t\t\t priorities, including research on AIDS, AIDS vaccines, and medicines for\n\t\t\t responding to bioterrorism."}, "enum": {"#tail": "\n          ", "#text": "(3)"}, "@id": "ID4b8bfe1fb721457b9a52a9bed1f9b7a6", "#text": "\n          "}], "#text": "\n        ", "@id": "ID5afb62e4ca914a0da15779adbc8c8188"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ") shall\u2014", "@entity-type": "act", "#text": "section 8(b)(3)", "@value": "Medical Innovation Prize Fund Act/s:8/ss:b/p:3", "@proposed": "true"}, "#text": "The advisory committee on research and\n\t\t\t development priorities (established pursuant to "}, "enum": {"#tail": "\n        ", "#text": "(c)"}, "header": {"#tail": "\n        ", "#text": "Public input;\n\t\t\t recommendations"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "solicit public\n\t\t\t input on research and development priorities; and"}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "ID112258060783406985f76ad36e78de16", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " modifications in the minimum levels of funding for\n\t\t\t prizes for priority research and development under this section.", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, "#text": "periodically\n\t\t\t recommend to the "}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "ID80095fe4a5714fa1870f78642962da38", "#text": "\n          "}], "#text": "\n        ", "@id": "IDbc52c29b864842c7aad2490bcbbe3947"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall adopt procedures to establish and periodically modify minimum\n\t\t\t levels of funding under ", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, {"#tail": " for priority research and development.", "@entity-type": "act", "#text": "section 9", "@value": "Medical Innovation Prize Fund Act/s:9", "@proposed": "true"}], "#text": "The\n\t\t\t "}, "enum": {"#tail": "\n        ", "#text": "(d)"}, "header": {"#tail": "\n        ", "#text": "Procedures"}, "#text": "\n        ", "@id": "ID5a10e8716b894f6181ae1bb976fe1392"}], "#text": "\n      ", "@id": "id7C82F1A8B8FD4CA08718792ABD6C039C"}, {"#tail": "\n    ", "enum": {"#tail": "\n      ", "#text": "11."}, "header": {"#tail": "\n\t\t\t", "#text": "Open source\n\t\t\t dividend prizes"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "In order to induce greater access and the open sharing of\n\t\t\t knowledge, data, materials and technology, at least 5 percent of the prize\n\t\t\t payments from the Fund shall be dedicated to Open Source Dividend\n\t\t\t prizes."}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "In\n\t\t\t general"}, "#text": "\n        ", "@id": "idB5D926D2E25449C086149428E908C61D"}, {"#tail": "\n    ", "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n\t\t\t\t", "#text": "Procedures"}, "paragraph": [{"#tail": "\n        ", "@id": "id2518C71E7AAE4C4686259FC7DEB211B7", "enum": {"#tail": "\n          ", "#text": "(1)"}, "header": {"#tail": "\n          ", "#text": "In\n\t\t\t general"}, "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall adopt procedures for the\n\t\t\t allocation of Open Source Dividend prizes. Such procedures shall\u2014", "@entity-type": "federal-body", "#text": "Board of Trustees", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, "#text": "The "}, "#text": "\n          ", "subparagraph": [{"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "be fully\n\t\t\t transparent regarding the process for evaluating the value of open sharing of\n\t\t\t knowledge, data, materials, and technology;"}, "enum": {"#tail": "\n            ", "#text": "(A)"}, "@id": "ID0b7afc7e047e40918c4fc71826c79fd7", "#text": "\n            "}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " and\n\t\t\t ", "@entity-type": "act", "#text": "sections 9", "@value": "Medical Innovation Prize Fund Act/s:9", "@proposed": "true"}, {"#tail": ";", "@entity-type": "act", "#text": "10", "@value": "Medical Innovation Prize Fund Act/s:10", "@proposed": "true"}], "#text": "reward the open,\n\t\t\t nondiscriminatory and royalty-free sharing of knowledge, data, materials, and\n\t\t\t technology that has contributed to the development of the new drugs, biological\n\t\t\t products, or manufacturing processes that are rewarded under "}, "enum": {"#tail": "\n            ", "#text": "(B)"}, "@id": "ID499f0aa6bbd34d99a7062ee3f1183535", "#text": "\n            "}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " and ", "@entity-type": "act", "#text": "sections 9", "@value": "Medical Innovation Prize Fund Act/s:9", "@proposed": "true"}, {"#tail": ", provide for a\n\t\t\t time-limited period of nominations for persons or communities whose\n\t\t\t contributions were considered useful, including the evidence to support such\n\t\t\t nominations to describe the significance of the contribution; and", "@entity-type": "act", "#text": "10", "@value": "Medical Innovation Prize Fund Act/s:10", "@proposed": "true"}], "#text": "in the case of\n\t\t\t rewards for contributing to the development of new drugs, biological products,\n\t\t\t or manufacturing processes rewarded under "}, "enum": {"#tail": "\n            ", "#text": "(C)"}, "@id": "ID7a63de3ccd8d4b6d8b2c3d0459722ade", "#text": "\n            "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "provide for rules\n\t\t\t and procedures to protect against conflicts of interest."}, "enum": {"#tail": "\n            ", "#text": "(D)"}, "@id": "ID093ae7aae63848ec95136d5ca4efb555", "#text": "\n            "}]}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", and the evidence supporting such nominations, shall be\n\t\t\t public. The public shall be allowed to provide commentary and additional\n\t\t\t evidence on such nominations before awards are made.", "@entity-type": "act", "#text": "paragraph (1)(C)", "@value": "Medical Innovation Prize Fund Act/s:11/ss:b/p:1/sp:C", "@proposed": "true"}, "#text": "The nominations described in\n\t\t\t "}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "header": {"#tail": "\n          ", "#text": "Public\n\t\t\t availability of nominations"}, "#text": "\n          ", "@id": "idADA372C1F6214C3D80810A44071B2093"}], "#text": "\n        ", "@id": "ID301816fbe6e941498ffd75a4196d2716"}], "#text": "\n      ", "@id": "idADDD257E113E46A3839F50EDAB9BAA0D"}, {"#tail": "\n    ", "enum": {"#tail": "\n      ", "#text": "12."}, "header": {"#tail": "\n\t\t\t", "#text": "Competitive\n\t\t\t intermediaries for funding interim technologies"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " may authorize multiple nonprofit\n\t\t\t intermediaries to reward projects for interim research and development of\n\t\t\t products, or for open source dividend prizes. Such intermediaries shall compete\n\t\t\t for funding from non-Federal entities that co-fund the Fund.", "@entity-type": "federal-body", "#text": "Board of Trustees", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, "#text": "The "}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "In\n\t\t\t general"}, "#text": "\n        ", "@id": "idA3689D4B28534412B5310FA49BA5BA08", "@commented": "no"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "Prizes\n\t\t\t awarded by competitive intermediaries shall be available to persons or\n\t\t\t communities that provide open, nondiscriminatory and royalty-free licenses to\n\t\t\t relevant intellectual property rights."}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Availability"}, "#text": "\n        ", "@id": "IDed9be2a0261d447bb63099affa9481cc", "@commented": "no"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall adopt rules to ensure the transparency and\n\t\t\t accountability of any entities authorized to act as competitive intermediaries\n\t\t\t under ", "@entity-type": "federal-body", "#text": "Board of Trustees", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, {"#tail": ".", "@entity-type": "act", "#text": "subsection (a)", "@value": "Medical Innovation Prize Fund Act/s:12/ss:a", "@proposed": "true"}], "#text": "The\n\t\t\t "}, "enum": {"#tail": "\n        ", "#text": "(c)"}, "header": {"#tail": "\n        ", "#text": "Rules"}, "#text": "\n        ", "@id": "IDd66521a995c3497f9a09647ffa1589f3", "@commented": "no"}], "#text": "\n      ", "@id": "idE50F415E58D44AC99C3413D17941FF82"}, {"#tail": "\n    ", "enum": {"#tail": "\n      ", "#text": "13."}, "header": {"#tail": "\n\t\t\t", "#text": "Special\n\t\t\t transition rules"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "section 9(d)(3)", "@value": "Medical Innovation Prize Fund Act/s:9/ss:d/p:3", "@proposed": "true"}, "#text": "A drug or biological product that is on the market on\n\t\t\t October 1, 2014, shall remain eligible for prize payments for not more than 10\n\t\t\t fiscal years, consistent with "}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "In\n\t\t\t general"}, "#text": "\n        ", "@id": "id01A06F1BC24A4851B50B8ED736E88291"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", the ", "@entity-type": "act", "#text": "subsection (a)", "@value": "Medical Innovation Prize Fund Act/s:13/ss:a", "@proposed": "true"}, {"#tail": " shall calculate\n\t\t\t the incremental value of the drug or biological product as of the date on which\n\t\t\t the drug or biological product was first introduced in the market.", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}], "#text": "In determining the amount of a prize payment for a drug\n\t\t\t or biological product described in "}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Determination\n\t\t\t of value"}, "#text": "\n        ", "@id": "id7EDAEBCBE9CD46F29CE9B66471882C96"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", the ", "@entity-type": "act", "#text": "subsection (a)", "@value": "Medical Innovation Prize Fund Act/s:13/ss:a", "@proposed": "true"}, {"#tail": " may award\u2014", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}], "#text": "With respect to drugs and biological products described in\n\t\t\t "}, "enum": {"#tail": "\n        ", "#text": "(c)"}, "header": {"#tail": "\n        ", "#text": "Maximum\n\t\t\t amount"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "of the amount\n\t\t\t appropriated to the Fund for fiscal year 2015, not more than 90 percent of such\n\t\t\t amount; and"}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "IDfec260897a3c42699f8b7f061e3054a7", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "of the amount\n\t\t\t appropriated to the Fund for each of the succeeding 9 fiscal years, not more\n\t\t\t than a percentage of such amount that is equal to 9 percent less the percentage\n\t\t\t applicable to the preceding fiscal year under this subsection."}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "IDe888c1a657d84ae3aad0ced297c307cc", "#text": "\n          "}], "#text": "\n        ", "@id": "id5D48DE904249462CB1CF2FF7D30B2045"}], "#text": "\n      ", "@id": "id080A4D075E40426583F8651FF6EFEA89"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall\n\t\t\t establish an arbitration procedure to determine an equitable division of any\n\t\t\t prize payments under this Act among the patent owners and the person who first\n\t\t\t received market clearance for the drug.", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, "#text": "In the case of a drug that is on the market\n\t\t\t on October 1, 2014, and subject to patents owned by a party other than the\n\t\t\t person who first received market clearance for the drug, the ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "14."}, "header": {"#tail": "\n      ", "#text": "Arbitration"}, "#text": "\n      ", "@id": "idF3882A5CCECD4AF8BCFF08F58D9D4752"}, {"#tail": "\n    ", "enum": {"#tail": "\n      ", "#text": "15."}, "header": {"#tail": "\n\t\t\t", "#text": "Annual audits\n\t\t\t by GAO"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall conduct an audit of the ", "@entity-type": "federal-body", "#text": "Comptroller General of the United States", "@entity-id": "0500"}, {"#tail": "\n\t\t\t each fiscal year to determine the effectiveness of the ", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, {"#tail": "\u2014", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}], "#text": "The\n\t\t\t "}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "Audits"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "in bringing to\n\t\t\t market drugs, vaccines and other biological products, and new manufacturing\n\t\t\t processes for medicines in a cost-effective manner; and"}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "IDe2cdb2f9e3704508a0859258feaf4404", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "in addressing\n\t\t\t society's medical needs, including global neglected diseases that afflict\n\t\t\t primarily the poor in developing countries, indications for which orphan\n\t\t\t designation has been granted under ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ", and global infectious diseases and other global\n\t\t\t public health priorities.", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 526 of the Federal Food, Drug, and\n\t\t\t Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:526"}, "@entity-type": "law-citation", "#text": "\n              ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n              ", "@entity-type": "uscode", "#text": "21 U.S.C. 360bb", "@value": "usc/21/360bb"}, "@parsable-cite": "usc/21/360bb", "#text": "\n                ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "IDd9fec3171f0a4bc991e798d10fd1ef05", "#text": "\n          "}], "#text": "\n        ", "@id": "idC1F70C8E79494997B5F15B563BA19EF5"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall submit a report to the ", "@entity-type": "federal-body", "#text": "Comptroller General of the United States", "@entity-id": "0500"}, {"#tail": "\n\t\t\t each fiscal year on the results of each audit conducted under ", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}, {"#tail": ".", "@entity-type": "act", "#text": "subsection\n\t\t\t (a)", "@value": "Medical Innovation Prize Fund Act/s:15/ss:a", "@proposed": "true"}], "#text": "The\n\t\t\t "}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Reports"}, "#text": "\n        ", "@id": "ID8bfc62bfe63c4e76a6d2b56c4e94a1c8"}], "#text": "\n      ", "@id": "id5D5A9F33D36E4165BA91B4BD332E04DA"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall submit to ", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, {"#tail": "\n\t\t\t a report containing the findings, conclusions, and recommendations of the ", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}, {"#tail": "\n\t\t\t concerning the implementation and administration of this Act, including\n\t\t\t recommendations for such legislative and administrative action as the ", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}, {"#tail": "\n\t\t\t determines to be appropriate.", "@entity-type": "federal-body", "#text": "Board", "@value": "Board of Trustees for the Fund for Medical Innovation Prizes", "@proposed": "true"}], "#text": "Not later than 1 year\n\t\t\t after the date of the enactment of this Act, the ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "16."}, "header": {"#tail": "\n      ", "#text": "Report to\n\t\t\t Congress"}, "#text": "\n      ", "@id": "id0377381339E34A769912175409CBFD46"}, {"#tail": "\n    ", "enum": {"#tail": "\n      ", "#text": "17."}, "header": {"#tail": "\n\t\t\t", "#text": "Funding"}, "subsection": [{"#tail": "\n      ", "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n\t\t\t\t", "#text": "Appropriations"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "\n            ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": "\n          ", "@entity-type": "auth-auth-approp", "#text": "\n              ", "{http://namespaces.cato.org/catoxml}funds-and-year": {"#tail": " ", "#text": "For fiscal year 2015, there are authorized to be\n\t\t\t appropriated to the Fund, such sums as may be necessary", "@amount": "indefinite", "@year": "2015"}, "{http://namespaces.cato.org/catoxml}property": {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n              ", "@entity-type": "act", "#text": "this\n\t\t\t Act", "@value": "Medical Innovation Prize Fund Act", "@proposed": "true"}, "#text": "to carry out ", "@name": "purpose"}}}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "header": {"#tail": "\n          ", "#text": "Start-up\n\t\t\t costs"}, "#text": "\n          ", "@id": "idC05C28EE1A924FE79D62F374750010EC"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "\n            ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ").", "@entity-type": "federal-body", "#text": "Secretary of Commerce"}, "@entity-type": "auth-auth-approp", "#text": "For fiscal year 2015 and each subsequent fiscal\n\t\t\t year, there is appropriated to the Fund, out of any funds in the Treasury not\n\t\t\t otherwise appropriated, ", "{http://namespaces.cato.org/catoxml}funds-and-year": {"#tail": "\n\t\t\t (as such amount is determined by the ", "#text": "an amount equal to the amount that is .55 percent of\n\t\t\t the gross domestic product of the United States for the preceding fiscal year", "@amount": "indefinite", "@year": "2015,.."}}}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "header": {"#tail": "\n          ", "#text": "Program\n\t\t\t implementation"}, "#text": "\n          ", "@id": "ID276e2d0aa8c14e24b71581179cddf6b6"}], "#text": "\n        ", "@id": "id9F5FD9193DAD464F83CCA8BA36D076E9"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "#text": "Funds\n\t\t\t appropriated to the Fund for a fiscal year shall remain available for\n\t\t\t expenditure in accordance with this Act until the end of the 3-year period\n\t\t\t beginning on October 1 of such fiscal year. Any such funds that are unexpended\n\t\t\t at the end of such period shall revert to the Treasury."}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Availability"}, "#text": "\n        ", "@id": "idC493C3622C4C45BEB0C8123772116D1D"}], "#text": "\n      ", "@id": "id16A750256D414BDF9805CD6DF0B9823B"}, {"#tail": "\n  ", "enum": {"#tail": "\n      ", "#text": "18."}, "header": {"#tail": "\n\t\t\t", "#text": "Imposition of\n\t\t\t annual fee on health insurance providers"}, "subsection": [{"#tail": "\n      ", "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n\t\t\t\t", "#text": "Imposition of\n\t\t\t fee"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " not later than the annual payment\n\t\t\t date of each calendar year beginning after 2014 a fee in an amount determined\n\t\t\t under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ".", "@entity-type": "act", "#text": "subsection (b)", "@value": "Medical Innovation Prize Fund Act/s:18/ss:b", "@proposed": "true"}], "#text": "Each covered entity engaged in the business of providing\n\t\t\t health insurance shall pay to the "}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "header": {"#tail": "\n          ", "#text": "In\n\t\t\t general"}, "#text": "\n          ", "@id": "id9276A6EA61914839A334ECB1AF479BCF", "@commented": "no"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", which in no event, may be later than September 30 of such calendar\n\t\t\t year.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "term": {"#tail": " means, with respect to any calendar year, a date determined by the\n\t\t\t ", "#text": "annual payment\n\t\t\t date"}, "#text": "For purposes of this section, the term "}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "header": {"#tail": "\n          ", "#text": "Annual payment\n\t\t\t date"}, "#text": "\n          ", "@id": "id8A2AFACEE31341DBA9EA76F3C15F78ED", "@commented": "no"}], "#text": "\n        ", "@id": "id5509F27D7DD54427B65E2FC1D1163010", "@commented": "no"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", multiplied by the ratio of the covered entity\u2019s net\n\t\t\t premiums written with respect to health insurance for any United States health\n\t\t\t risk taken into account under ", "@entity-type": "act", "#text": "section 17(a)(2)", "@value": "Medical Innovation Prize Fund Act/s:17/ss:a/p:2", "@proposed": "true"}, {"#tail": " during the preceding calendar\n\t\t\t year, to\u2014", "@entity-type": "act", "#text": "subsection (c)", "@value": "Medical Innovation Prize Fund Act/s:18/ss:c", "@proposed": "true"}], "#text": "With respect to each covered entity, the fee under\n\t\t\t this section for any calendar year shall be equal to the amount determined\n\t\t\t under "}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Determination\n\t\t\t of fee amount"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "the sum of net\n\t\t\t premiums for all covered entities; and"}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "#text": "\n          ", "@id": "idE94EAE0C86AA43B5A24B8FBCB71E8BF6", "@commented": "no"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "all Federal\n\t\t\t outlays on health insurance or reimbursement of health care costs, excluding\n\t\t\t the costs of long term care."}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "#text": "\n          ", "@id": "id5B83782182A34105865E24A1CFF8F80F", "@commented": "no"}], "#text": "\n        ", "@id": "id37D1A95AC77E4A12986CF377CCCE1D78", "@commented": "no"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", the net premiums\n\t\t\t written with respect to health insurance for any United States health risk that\n\t\t\t are taken into account during any calendar year with respect to any covered\n\t\t\t entity shall be determined as follows:", "@entity-type": "act", "#text": "paragraph (b)", "@value": "Medical Innovation Prize Fund Act/s:18/ss:b", "@proposed": "true"}, "#text": "For purposes of "}, "enum": {"#tail": "\n        ", "#text": "(c)"}, "header": {"#tail": "\n        ", "#text": "Amounts taken\n\t\t\t into account"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "With respect to a\n\t\t\t covered entity\u2019s net premiums written during the calendar year that are not\n\t\t\t more than $25,000,000, the percentage of net premiums written that are taken\n\t\t\t into account is 0 percent."}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "idE11E8A5787AC4FD4A214B83380C0F0F2", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "With respect to a\n\t\t\t covered entity\u2019s net premiums written during the calendar year that are more\n\t\t\t than $25,000,000 but less than $50,000,000, the percentage of net premiums\n\t\t\t written that are taken into account is 50 percent."}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "idB938B34EF79D401B8D3FE259B4D724C3", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "With respect to a\n\t\t\t covered entity\u2019s net premiums written during the calendar year that are\n\t\t\t $50,000,000 or more, the percentage of net premiums written that are taken into\n\t\t\t account is 100 percent."}, "enum": {"#tail": "\n          ", "#text": "(3)"}, "@id": "id4D0162576CEB4DF1B1F9A5FDD1962879", "#text": "\n          "}], "#text": "\n        ", "@id": "IDd51fefb2e1384e89b050dc895979b22d"}, {"#tail": "\n    ", "enum": {"#tail": "\n        ", "#text": "(d)"}, "header": {"#tail": "\n\t\t\t\t", "#text": "Covered\n\t\t\t entity"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "term": {"#tail": " means any entity which provides health insurance for any United\n\t\t\t States health risk.", "#text": "covered\n\t\t\t entity"}, "#text": "For purposes of this section, the term "}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "header": {"#tail": "\n          ", "#text": "In\n\t\t\t general"}, "#text": "\n          ", "@id": "IDd75887a7ce3f4b14be589c3da784b734"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "Such\n\t\t\t term does not include any governmental entity."}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "header": {"#tail": "\n          ", "#text": "Exclusion"}, "#text": "\n          ", "@id": "ID2e06316d8f494c8eb2f20252d9d10e7d"}], "#text": "\n        ", "@id": "idC5B572237568443390CACF72F2608F4E"}], "#text": "\n      ", "@id": "id208627C53AB4429F9C431FB9E9737BAD", "@commented": "no"}], "#text": "\n\t\t"}, "metadata": {"#tail": "\n", "dublinCore": {"{http://purl.org/dc/elements/1.1/}date": {"#tail": "\n", "#text": "2013-03-20"}, "{http://purl.org/dc/elements/1.1/}format": {"#tail": "\n", "#text": "text/xml"}, "{http://purl.org/dc/elements/1.1/}language": {"#tail": "\n", "#text": "EN"}, "#tail": "\n", "{http://purl.org/dc/elements/1.1/}title": {"#tail": "\n", "#text": "113 S627 IS: Medical Innovation Prize Fund Act"}, "{http://purl.org/dc/elements/1.1/}rights": {"#tail": "\n", "#text": "Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain."}, "{http://purl.org/dc/elements/1.1/}publisher": {"#tail": "\n", "#text": "U.S. Senate"}, "#text": "\n"}, "#text": "\n"}}}